$979.6 million is the projected size of the pharma-grade dummy pellets market by 2036, up from $512.2 million in 2026, according to the latest forecast.
6.7% annual growth is tied to demand for dose uniformity, coating performance, release behavior and GMP documentation, with buyers requiring documented proof before shifting from trials to recurring orders.
North America is expected to lead with a 37.9% regional share in 2026, while sugar spheres hold 36.6% of the core-substrate segment and pharma companies account for 36.5% of end-user demand.
India shows the fastest country growth at a 5.7% CAGR through 2036, ahead of China at 4.3% and the United States at 2.9%, reflecting uneven adoption across markets.
Competition centers on technical validation and compliance support, with Glatt, Aenova, Lonza, Colorcon, JRS Pharma, Roquette and Evonik among the notable suppliers.